YOLFTbeta
MEDIPOST Co. Ltd

MEDIPOST Co. Ltd

078160 · KQ · Healthcare / Biotechnology & Medical Research

8,130.00KRW-290.00 (-3.44%)

Price History

Full chart

Market Stats

Previous Close8,420.00
Open8,400.00
Day Range8,110.00 – 8,610.00
52-Week Range7,250.00 – 29,100.00
Volume74.19K
Market Cap365.06B
P/E (TTM)0.00
Forward P/E277.78
Dividend Yield0.00%
Beta0.78
50-Day Avg9,028.20
200-Day Avg15,757.75

About

MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell drugs, such as PNEUMOSTEM, which is in completed Phase II clinical trial in South Korea, as well as in Phase I/II clinical trial in the United States for the preventative treatment of bronchopulmonary dysplasia; and NEUROSTEM that is in Phase I/IIa clinical study to treat Alzheimer's disease. Further, the company develops SMUP-IA-01, which has completed phase I clinical trial for the treatment of osteoarthritis; and SMUP-IV-01 for the treatment of diabetic nephropathy, as well as offers nutritional and dietary supplements under the MOVITA brand name. MEDIPOST Co., Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology & Medical Research
  • CEODr. Yoon-Seon Yang
  • Employees271
  • Headquarters21, Daewangpangyo-ro, Seongnam-si, South Korea, Korea
  • Websitehttps://www.medi-post.co.kr

Leadership

  • Dr. Won-II Oh M.D., Ph.D.Gen. Director of Laboratory, VP and Director · b. 1962
  • Mr. Jang-Won LeeSr. Managing Director and Exec. Director · b. 1966
  • Dr. Yoon-Seon YangCEO & Pres · b. 1964
  • Dr. Sung-Ho Han Ph.D.Head Mang. of Bus. Devel. Division and Director · b. 1970
  • Dr. Soo-Jin Choi M.D., Ph.D.Director of Research Department and Director · b. 1971
  • Mr. Young-Hwan SongHead Mang. of Management Support Division and Director · b. 1966
  • Ms. Hye-Kyung HongDirector of 1st Research Department and Director · b. 1969

Financials

Income Statement

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue35.54B40.77B41.50B41.40B37.57B28.65B42.25B44.38B45.81B48.62B54.86B64.20B68.64B70.66B73.66B
Growth (%)-+14.72%+1.80%-0.24%-9.26%-23.73%+47.45%+5.05%+3.22%+6.14%+12.82%+17.03%+6.92%+2.93%+4.25%
Cost of Revenue15.40B20.54B19.53B20.30B15.58B12.95B17.05B16.02B16.79B17.73B22.99B25.83B28.46B26.52B28.22B
Gross Profit---18.38B21.99B15.70B25.20B28.36B29.02B30.89B31.86B38.37B40.18B44.14B45.44B
Gross Margin---44.39%58.53%54.79%59.64%63.91%63.36%63.53%58.08%59.77%58.54%62.47%61.69%
Operating Expense---20.15B25.96B25.75B29.88B34.96B37.23B33.30B35.23B58.61B35.12B110.12B113.42B
Operating Income4.23B---1.77B-3.97B-10.05B-4.68B-6.59B-8.20B-2.41B-3.37B-20.24B5.07B-65.98B-67.98B
Operating Margin11.90%---4.29%-10.57%-35.06%-11.09%-14.85%-17.91%-4.96%-6.13%-31.52%7.38%-93.38%-92.30%
EBITDA-----------20.17B16.67B-56.41B-79.35B
EBITDA Margin-----------31.41%24.29%-79.84%-107.73%
Net Income4.40B1.70B995.64M-1.85B2.78B-5.37B-949.87M-2.01B-14.12B-1.90B-683.26M3.07B5.84B-62.52B-85.40B
Net Income Margin12.39%4.16%2.40%-4.47%7.40%-18.73%-2.25%-4.52%-30.82%-3.90%-1.25%4.78%8.51%-88.49%-115.94%
R&D1.29B-12.27B2.08B2.58B11.49B7.37B9.33B12.66B9.44B11.70B19.00B29.22B54.64B71.31B
R&D as % of Total Revenue3.63%-29.57%5.03%6.87%40.10%17.45%21.01%27.64%19.42%21.33%29.60%42.56%77.33%96.81%
Interest Expense0000000006.14B3.56B8.28B6.39B499.28M533.20M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%12.62%6.48%12.89%9.31%0.71%0.72%

Balance Sheet

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets131.79B137.44B145.77B185.97B182.93B179.26B144.65B175.75B213.72B219.81B254.09B397.79B449.39B414.29B431.55B
Total Liabilities16.75B20.21B28.35B68.63B36.45B35.95B40.20B48.94B102.13B103.27B94.61B217.82B135.74B161.69B181.64B
Total Equity114.29B116.41B116.42B116.58B146.48B143.31B104.45B126.81B111.59B116.54B159.48B179.97B311.55B251.31B249.02B
Cash21.88B8.71B12.68B30.44B22.91B7.46B9.06B6.32B11.91B8.22B9.72B14.85B37.52B32.67B76.93B
Total Debt----17.94B15.59B15.59B-35.32B10.27B-----
Net Debt--------23.06B31.61B17.36B32.92B---

Cash Flow

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.13B---1.49B-6.91B-12.42B-6.93B6.89B7.51B1.78B4.06B-6.19B-19.08B-37.27B-57.15B
Investing Cash Flow----22.12B-5.37B-10.99B3.23B-12.06B-36.26B-3.24B-8.19B-107.88B-28.09B31.38B-
Financing Cash Flow52.53B1.49B9.27B43.06B5.54B8.01B2.72B2.43B34.34B-1.11B5.66B118.54B70.16B-1.08B-
Capital Expenditure1.48B9.03B22.09B22.21B9.49B9.93B787.70M1.29B9.31B7.85B10.18B3.56B2.61B3.26B3.28B
Free Cash Flow---------4.17B-6.28B-6.65B-9.75B-21.69B-40.53B-60.42B
FCF to OCF---------55.46%-351.90%-163.89%157.42%113.70%108.75%105.73%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Nov 3, 2014Feb 10, 2015Apr 16, 2015Aug 4, 2015Nov 6, 2015Feb 3, 2016May 2, 2016Aug 5, 2016Nov 3, 2016Feb 7, 2017May 4, 2017Jul 31, 2017Nov 2, 2017Feb 7, 2018May 11, 2018Aug 14, 2018Nov 14, 2018Feb 7, 2019May 3, 2019Aug 2, 2019Nov 13, 2019Feb 10, 2020May 15, 2020Aug 7, 2020Nov 15, 2020Feb 15, 2021May 16, 2021Aug 17, 2021Nov 14, 2021Feb 14, 2022May 6, 2022Aug 5, 2022Nov 4, 2022Feb 6, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 28, 2024May 14, 2024Aug 14, 2024Nov 12, 2024Feb 19, 2025May 14, 2025Aug 12, 2025Nov 12, 2025Feb 18, 2026Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------------------------------
EPS Actual-35.32-17.66-14.83-0.43-6.7757.8051.9832.77177.5578.31112.78-73.8475.09-46.11-20.54126.1170.29-81.2071.515.68-61.60-17.416.385.51147.99145.88-68.08-31.02-34.76-138.85-92.20-80.5187.8171.12-80.00-172.23-137.5018.50-71.58118.0049.00118.00-76.21-976.92258.00-45.00-334.000.30-368.0031.00-2.00288.34-402.40-705.00991.00191.47-388.08218.50-137.81339.20-200.6283.63-534.12-1182.03-480.38-708.92-535.81-711.82-269.92-46.68
Surprise----------------------------------------------------------------------
Timing----------------------Pre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market--

Key Statistics & Ratios

Market Cap365.06B
Enterprise Value317.17B
Trailing P/E0.00
Forward P/E277.78
Price / Sales5.31
Price / Book1.28
Revenue (TTM)62.41B
Gross Profit (TTM)31.86B
EBITDA-10.80B
Profit Margin4.44%
Operating Margin-26.25%
Return on Equity-2666.52%
Return on Assets-3.47%
Shares Outstanding15.38M
Shares Float12.69M
Beta0.78
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 19, 2023339:298
  • Mar 29, 20192:1
  • Oct 7, 2011347:336
  • Jan 31, 2006951:881